After a ‘breakthrough’ beginning to 2020, little Aprea gets crushed by a PhIII failure

Boston-based biotech Aprea Therapeutics $APRE started the year with a promising breakthrough therapy designation from the FDA for its lead p53 reactivating program for eprenetapopt. And it’s ending the year with a Phase III failure for the drug.